Should the Pharmaceutical Industry be doing more to Reduce the Cost of Cancer Drugs?

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|41|1|4-5

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.41, Iss.1, 2011-03, pp. : 4-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Homochiral Drugs: A Demanding Tendency of the Pharmaceutical Industry

By  

Current Medicinal Chemistry, Vol. 16, Iss. 16, 2009-06 ,pp. : 2064-2074

Bentham Science Publishers

Access to resources Recommend Favorite

High-dose fluconazole should reduce mortality at acceptable cost

By  

Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

High-dose fluconazole should reduce mortality at acceptable cost

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Barriers to the uptake of new high-cost cancer drugs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The US-based Pew Charitable Trusts is funding a campaign called the Prescription Project to reduce the influence of pharmaceutical industry marketing on physicians

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite